STOCK TITAN
  1. Home
  2. News
  3. MNOV

Medicinova Inc - MNOV STOCK NEWS

Welcome to our dedicated news page for Medicinova (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicinova's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicinova's position in the market.

News
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Rhea-AI Summary
MediciNova, Inc. announced the selection of an abstract for an oral presentation at the 2024 ASCO Annual Meeting on the results of a clinical trial of MN-166 in glioblastoma. The presentation will be given by Dr. Gilbert Youssef, detailing a Phase 1b/2a study on the combination of MN-166 and temozolomide in patients with newly diagnosed and recurrent GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
clinical trial
-
News
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Rhea-AI Summary
MediciNova, Inc. receives a Notice of Allowance from the Japan Patent Office for a pending patent application covering MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039 and covers a wide range of doses, dosing frequencies, and treatment periods. Chief Medical Officer, Kazuko Matsuda, highlights the potential value of MN-166 in ophthalmic neurodegenerative diseases based on positive data from previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
none
-
News
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
Rhea-AI Summary
MediciNova, Inc. announces abstracts on MN-001's efficacy in NAFLD, HTG, and T2DM accepted for EAS 2024 Congress. Chief Medical Officer to present ongoing clinical trial design and results of research on MN-001 and MN-002.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
News
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
Rhea-AI Summary
MediciNova, Inc. announces positive results from a nonclinical study evaluating MN-166 (ibudilast) in a chlorine gas-induced acute lung injury model. MN-166 showed significant improvements in pulmonary function, survival rates, and lung injury attenuation. The study highlighted the efficacy of MN-166 in treating acute lung injury, positioning it as a promising candidate for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
News
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
Rhea-AI Summary
MediciNova, Inc. has received a Notice of Grant from the Chinese Patent Office for a new patent covering MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than April 2040 and covers a wide range of doses, dosing frequencies, and treatment periods. The Chief Medical Officer commented on the potential of MN-166 in ophthalmic neurodegenerative diseases and the positive data from previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
News
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) announced the selection of an abstract for a poster presentation at the Society of Toxicology 63rd Annual Meeting and ToxExpo, detailing the results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury. The study will be presented by collaborator Perenlei Enkhbaatar, MD, PhD, FAHA, and funded in part by the Department of Health and Human Services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
News
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) has received a Notice of Decision to Grant from the European Patent Office for a pending patent application covering the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039 and covers a wide range of doses, dosing durations, and frequencies for the combination. The company's Chief Medical Officer believes this new patent could increase the potential value of MN-166, indicating a synergistic effect of the combination in reducing the risk of disability progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
News
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) announced positive results from a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients. The trial evaluated the combination of MN-166 and anti-PD1 or anti-PD-L1 therapy in GBM models. The primary endpoints were safety, tolerability, and efficacy. MN-166 and TMZ combination treatment was safe and well-tolerated, with a PFS6 rate of 44% for new GBM and 31% for recurrent GBM. Preclinical studies showed that adding MN-166 to anti-PD1 or anti-PD-L1 therapy significantly extended survival. Chief Medical Officer, Kazuko Matsuda, expressed excitement for the findings and future trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.73%
Tags
clinical trial
-
News
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
Rhea-AI Summary
MediciNova announces first patient treated in clinical trial for SAR444836 gene therapy for PKU
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
clinical trial
News
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
Rhea-AI Summary
MediciNova receives Notice of Allowance for ALS treatment patent
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock MNOV logo
Medicinova Inc

Nasdaq:MNOV

MNOV Rankings

#4518 Ranked by Market Cap
#2373 Ranked by Stock Gains
N/A Ranked by Dividends

MNOV Stock Data

77.00M
42.28M
2.56%
21.14%
0.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
La Jolla

About MNOV

pharmaceutical preparations